Isthmus Partners LLC Acquires Shares of 9,622 Henry Schein, Inc. (NASDAQ:HSIC)

Isthmus Partners LLC bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,622 shares of the company’s stock, valued at approximately $701,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. ING Groep NV purchased a new position in Henry Schein in the 3rd quarter worth $63,226,000. Thompson Siegel & Walmsley LLC purchased a new position in shares of Henry Schein during the 2nd quarter valued at about $46,683,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Henry Schein during the 3rd quarter valued at about $43,740,000. Bank of Montreal Can raised its stake in shares of Henry Schein by 365.6% during the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock valued at $52,095,000 after buying an additional 558,689 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in shares of Henry Schein by 1,622.3% during the 3rd quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after acquiring an additional 432,187 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $77.05 on Friday. The company has a 50-day simple moving average of $71.36 and a 200-day simple moving average of $69.89. Henry Schein, Inc. has a one year low of $63.67 and a one year high of $82.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.82 and a current ratio of 1.42. The stock has a market capitalization of $9.61 billion, a price-to-earnings ratio of 31.71, a PEG ratio of 2.23 and a beta of 0.87.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.05. The firm had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm’s revenue for the quarter was up .4% on a year-over-year basis. During the same period in the prior year, the company posted $1.32 earnings per share. On average, analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current year.

Insider Buying and Selling

In related news, COO Michael S. Ettinger sold 12,240 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the transaction, the chief operating officer now directly owns 87,706 shares of the company’s stock, valued at $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Lorelei Mcglynn sold 21,035 shares of the company’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at $4,978,026.90. The trade was a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Barrington Research reiterated an “outperform” rating and issued a $82.00 price objective on shares of Henry Schein in a report on Wednesday, November 6th. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday, November 7th. Robert W. Baird reduced their price target on shares of Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. JPMorgan Chase & Co. cut their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Finally, Evercore ISI boosted their price target on shares of Henry Schein from $70.00 to $74.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 8th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.